10-Q: Adagio Medical Reports Q3 Loss, Secures $19M Funding

Adagio Medical Holdings, Inc. reported a significant net loss for Q3 2025, alongside a recent $19 million private placement and progress in its FULCRUM-VT clinical trial.

Summary

• Adagio Medical Holdings, Inc. (ADGM) reported a net loss of $10.1 million for the three months ended September 30, 2025, and $21.8 million for the nine months ended September 30, 2025.
• Revenue for both the three and nine months ended September 30, 2025, was nil, primarily due to a pause in European commercial activity and an inventory buyback.
• Cash and cash equivalents decreased significantly to $4.7 million as of September 30, 2025, from $20.6 million at December 31, 2024.
• The company completed enrollment in its FULCRUM-VT U.S. IDE Pivotal Study in October 2025, evaluating its vCLAS Cryoablation System for ventricular tachycardia.
• In April 2025, the vCLAS Cryoablation System received Breakthrough Device designation from the FDA for treating drug-refractory, recurrent, sustained monomorphic ventricular tachycardia.
• A private placement completed in October 2025 raised approximately $19 million in gross proceeds, with potential for an additional $31 million from warrant exercises.
• The company implemented a corporate prioritization initiative in February 2025, focusing resources on the FULCRUM-VT trial and new product design optimization.
• An accumulated deficit of $92.3 million was reported as of September 30, 2025, up from $70.6 million at December 31, 2024.

Sentiment

Score: 4

Explanation: The company faces significant financial challenges with zero revenue and substantial net losses, leading to a low cash balance. However, the recent capital raise and positive clinical trial progress (FULCRUM-VT enrollment completion, FDA Breakthrough Device designation) provide a lifeline and future potential, preventing a lower score. The pause in European commercial activity is a negative operational development.

Positives

• Completed enrollment in the FULCRUM-VT U.S. IDE Pivotal Study in October 2025, a critical step towards potential FDA approval.
• Received Breakthrough Device designation from the FDA in April 2025 for the vCLAS Cryoablation System, which may facilitate a more interactive and timely regulatory review.
• Successfully secured approximately $19 million in gross proceeds from a private placement in October 2025, providing crucial liquidity, with potential for an additional $31 million from warrant exercises.
• Preliminary acute safety and efficacy results from the FULCRUM-VT trial show 97.4% acute clinical success and 96.7% elimination of clinically-relevant VTs, with a 2.5% rate of major adverse events.
• Developing a next-generation ULTC technology for VT designed for improved usability, smaller diameter, and a single-freeze ablation protocol.

Negatives

• Reported a net loss of $10.1 million for the three months ended September 30, 2025, and $21.8 million for the nine months ended September 30, 2025.
• Revenue was nil for both the three and nine months ended September 30, 2025, primarily due to a pause in European commercial activity and an inventory buyback.
• Cash and cash equivalents significantly decreased to $4.7 million as of September 30, 2025, from $20.6 million at December 31, 2024, indicating substantial cash burn.
• Accumulated deficit grew to $92.3 million as of September 30, 2025, from $70.6 million at December 31, 2024.
• Net cash used in operating activities was $14.9 million for the nine months ended September 30, 2025.
• Incurred a $3.5 million loss from convertible notes fair value adjustment and a $0.2 million loss from warrant liabilities fair value adjustment for the three months ended September 30, 2025.

Risks

• Ability to continue developing innovative products, obtain and maintain regulatory clearances/approvals, demonstrate safety/effectiveness in trials, increase physician awareness, and secure adequate reimbursement.
• Impact of international trade policies, including tariffs, sanctions, and trade barriers, particularly affecting U.S.-China trade relations, which could increase costs, reduce profitability, and delay development timelines.
• The corporate prioritization initiative may lead to unintended consequences such as loss of institutional knowledge, employee attrition, decreased morale, and may not achieve anticipated benefits.
• Changes in the regulatory landscape, policies, or processes, and disruptions at the FDA (e.g., layoffs, funding shortages) could negatively impact the business and delay product reviews/approvals.
• Breakthrough Device designation does not guarantee a faster development, regulatory review, or approval process, nor does it ensure ultimate PMA approval from the FDA.
• Uncertainty regarding the U.S. political environment, including legislative and regulatory proposals related to healthcare access, pricing transparency, domestic production, and tariffs, could adversely affect the business.
• Reliance on a limited number of suppliers, including sole source suppliers, which may impact the availability and cost of materials and instruments.

Future Outlook

The company believes its existing cash and cash equivalents, including the proceeds from the recent private placement, are sufficient to fund operating and capital expenditure requirements for at least 12 months from the issuance date of the financial statements. It plans to submit FULCRUM-VT trial results for FDA approval in the first half of 2026 and share six-month efficacy results in April 2026. Future funding requirements will depend on revenue growth, R&D efforts, sales and marketing activities, and the outcome of clinical trials.

Management Comments

• "We believe that our purpose-built solution has the potential to drive additional market growth in ablative treatment of the large, underserved VT patient population."
• "We plan to submit the results of this trial to support our application for U.S. Food and Drug Administration (FDA) approval of our vCLASTM Cryoablation System in the first half of 2026, and to share our six-month primary efficacy endpoint results of the FULCRUM-VT trial in April 2026 at the Heart Rhythm 2026 Conference."
• "We expect our selling, general, and administrative expenses to decrease slightly for the full year 2025 compared to the full year 2024. This anticipated decrease is primarily due to lower payroll and personnel expenses resulting from the corporate prioritization initiative implemented on February 28, 2025, as well as the absence of transaction-related costs incurred in connection with the Business Combination completed in 2024."
• "Based on our current forecast, we believe that we will have sufficient cash to maintain our planned operations for the next twelve months following the issuance of these condensed consolidated financial statements."

Industry Context

Adagio Medical operates in the highly competitive and rapidly evolving medical device industry, specifically targeting cardiac arrhythmias with novel cryoablation technologies. The focus on ventricular tachycardia (VT) addresses a significant unmet clinical need, as current radiofrequency (RF) ablation catheters are not optimally designed for ventricular anatomy. The development of next-generation ULTC and Pulsed Field Cryoablation (PFCA) technologies aligns with industry trends towards less invasive, more effective, and user-friendly ablation solutions. The FDA's Breakthrough Device designation highlights the potential for significant clinical benefit over existing treatments, positioning Adagio as a potential innovator in the cardiac electrophysiology market.

Comparison to Industry Standards

• The company's vCLAS Cryoablation System's preliminary acute safety and efficacy results (97.4% acute clinical success, 96.7% VT elimination, 2.5% major adverse events, 1.9% peri-procedural deaths, 0.5% device-related death) from the FULCRUM-VT trial will be compared against established treatments like radiofrequency (RF) ablation, which are currently used for VT despite being primarily designed for atrial fibrillation. Specific comparable companies or projects are not detailed in the filing, but the company states its approach offers a 'favorable combination of safety, acute and chronic effectiveness, compared to the current standard of care, including ablations performed using radiofrequency (RF) and pulsed field ablation (PFA) energy.'
• The CRYOCURE-VT trial outcomes (0% major adverse events, 94% acute procedural success, 60% freedom from sustained VT, 81% freedom from ICD shock at six months) for the vCLAS Cryoablation System in Europe and Canada provide a benchmark for its performance outside the U.S. pivotal trial.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently party to any material legal proceedings.

Related Party Transactions

• Incurred less than $0.01 million and $0.4 million in finance and accounting services and general administrative support from Fjord Ventures (owned by former CEO) for the three and nine months ended September 30, 2025, respectively.
• Perceptive PIPE Investor, a controlling party, received $7.0 million Convertible Securities Notes in exchange for February 2024 Convertible Notes.
• Perceptive PIPE Investor received 4,372,607 shares of common stock and 3,540,000 Base Warrants in exchange for Bridge Financing Notes and accrued interest.
• Perceptive PIPE Investor made an additional cash investment of approximately $15.9 million, receiving 2,250,352 shares of common stock and 1,905,069 Base Warrants.
• Entities affiliated with Perceptive Advisors LLC purchased Pre-Funded Warrants and Milestone Warrants for an aggregate purchase price of $4,250,000 in the October 2025 private placement.

Stakeholder Impact

• **Shareholders**: Experience significant dilution from recent and potential future capital raises, continued net losses, and accumulated deficit. However, clinical progress and FDA designation offer long-term upside potential.
• **Employees**: Affected by the corporate prioritization initiative in February 2025, which involved focusing resources and potentially led to headcount reductions, impacting morale and institutional knowledge. New equity incentive plans are in place to attract and retain talent.
• **Customers (Hospitals/Medical Centers)**: European commercial activity paused, impacting product availability in that market. U.S. customers are involved in the FULCRUM-VT trial, with potential for a new FDA-approved product in the future.
• **Creditors**: Convertible notes payable increased, indicating higher debt obligations. The recent private placement provides some liquidity to manage short-term obligations.
• **Suppliers**: Reliance on a limited number of suppliers, including sole source suppliers, poses risks to the supply chain and could impact product manufacturing and development timelines.

Next Steps

• Submit FULCRUM-VT trial results to the FDA for approval of the vCLAS Cryoablation System in the first half of 2026.
• Share six-month primary efficacy endpoint results of the FULCRUM-VT trial in April 2026 at the Heart Rhythm 2026 Conference.
• Continue development of a next-generation ULTC technology for VT, currently in the design phase.
• Manage discretionary spending and potentially raise additional financing if existing cash and capital raise proceeds are insufficient to meet liquidity requirements beyond 12 months.

Key Dates

Recommendation

The company is in a critical development phase with significant financial losses and cash burn, offset by promising clinical progress and a recent capital raise. The FDA Breakthrough Device designation and completion of FULCRUM-VT trial enrollment are positive catalysts, but commercialization is still in the future, and the European market pause is a setback. The recent private placement provides a temporary liquidity buffer, but further capital raises are likely. A 'hold' recommendation is appropriate for investors monitoring the company's progress towards FDA approval and successful commercialization, acknowledging both the high risk and high reward potential.

Keywords

Adagio Medical, ADGM, Cryoablation, Ventricular Tachycardia, Cardiac Arrhythmias, Medical Device, FDA Breakthrough Device, FULCRUM-VT, Clinical Trial, Pulsed Field Cryoablation, ULTC, SEC Filing, 10-Q, Financial Results, Capital Raise